• Cancer: Information theory to fight resi

    From ScienceDaily@1337:3/111 to All on Wed Jul 21 21:30:42 2021
    Cancer: Information theory to fight resistance to treatments

    Date:
    July 21, 2021
    Source:
    Universite' de Gene`ve
    Summary:
    A major challenge in cancer therapy is the adaptive response of
    cancer cells to targeted therapies. Although this adaptive response
    is theoretically reversible, such a reversal is hampered by numerous
    molecular mechanisms that allow the cancer cells to adapt to the
    treatment. A team has used information theory, in order to objectify
    in vivo the molecular regulations at play in the mechanisms of the
    adaptive response and their modulation by a therapeutic combination.



    FULL STORY ==========================================================================
    One of the major challenges in modern cancer therapy is the adaptive
    response of cancer cells to targeted therapies: initially, these
    therapies are very often effective, then adaptive resistance occurs,
    allowing the tumor cells to proliferate again. Although this adaptive
    response is theoretically reversible, such a reversal is hampered by
    numerous molecular mechanisms that allow the cancer cells to adapt to the treatment. The analysis of these mechanisms is limited by the complexity
    of cause and effect relationships that are extremely difficult to observe
    in vivo in tumor samples. In order to overcome this challenge, a team from
    the University of Geneva (UNIGE) and the University Hospitals of Geneva
    (HUG), Switzerland, has used information theory for the first time,
    in order to objectify in vivo the molecular regulations at play in the mechanisms of the adaptive response and their modulation by a therapeutic combination. These results are published in the journal Neoplasia.


    ========================================================================== Adaptive response limits the efficiency of targeted therapies used to
    fight the development of tumors: after an effective treatment phase
    that reduces the tumor size, an adaptation to the used molecule occurs
    that allows the tumor cells to proliferate again. "We now know that this resistance to treatment has a large reversible component that does not
    involve mutations, which are an irreversible process," explains Rastine
    Merat, a researcher in the Department of Pathology and Immunology at the
    UNIGE Faculty of Medicine, the head of the Onco-Dermatology Unit at the
    HUG and the principal investigator of the study.

    Research confronted with the complexity of biological regulations In
    order to prevent resistance to targeted therapies, scientists need to understand the molecular mechanisms of the adaptive response. "These
    mechanisms may involve variations in gene expression, for example,"
    explains Rastine Merat. It is then necessary to modify or prevent
    these variations by means of a therapeutic combination that blocks
    the consequences or even prevents them. One challenge remains: the
    description of these mechanisms and their modulation under the effect of
    a therapeutic combination is very often carried out on isolated cultured
    cells and not validated in tumor tissue in the body. "This is essentially
    due to the difficulty of objectifying these mechanisms, which may occur
    in a transient manner and only in a minority of cells in tumor tissues,
    and above all which involve non-linear cause and effect relationships," explains the Geneva researcher.

    Applying information theory to tumors To counter these difficulties,
    the UNIGE and HUG team came up with the idea of using information theory,
    more specifically by quantifying mutual information.

    This approach has previously been used in biology, mainly to quantify cell signaling and understand genetic regulation networks. "This statistical
    method makes it possible to link two parameters involved in a mechanism
    by measuring the reduction in the uncertainty of one of the parameters
    when the value of the other parameter is known," simplifies Rastine Merat.

    Practically, the scientists proceed step by step: they take biopsies of
    tumors (in this case melanomas) in a mouse model at different stages of
    their development during therapy. Using immunohistochemical analyses --
    i.e. tumor sections -- they measure, using an automated approach, the expression of proteins involved in the mechanism at play in the adaptive response. "The proposed mathematical approach is easily applicable to
    routine techniques such as immunohistochemistry and makes it possible
    to validate in vivo the relevance of the mechanisms under study,
    even if they occur in a minority of cells and in a transient manner,"
    the Geneva researcher explains. Thus, scientists can not only validate
    in the organism the molecular mechanisms they are studying, but also
    the impact of innovative therapeutic combinations that result from the understanding of these mechanisms. "Similarly, we could use this approach
    in therapeutic trials as a predictive marker of response to therapeutic combinations that seek to prevent adaptive resistance," he continues.

    A method suitable for all types of cancer "This method, developed in a
    melanoma model, could be applied to other types of cancer for which the
    same issues of adaptive resistance to targeted therapies occur and for
    which combination therapy approaches based on an understanding of the mechanisms involved are under development," concludes Rastine Merat.

    ========================================================================== Story Source: Materials provided by Universite'_de_Gene`ve. Note:
    Content may be edited for style and length.


    ========================================================================== Journal Reference:
    1. Aurore Bugi-Marteyn, Fanny Noulet, Nicolas Liaudet, Rastine Merat. A
    mutual information-based in vivo monitoring of adaptive response
    to targeted therapies in melanoma. Neoplasia, 2021; 23 (8): 775
    DOI: 10.1016/j.neo.2021.06.009 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2021/07/210721102254.htm

    --- up 10 weeks, 5 days, 22 hours, 45 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1337:3/111)